Divi's Laboratories Ltd.
NSE: DIVISLABDivi's Laboratories Ltd.: A 30-second snapshot
DIVISLAB trades at Rs 8,300, up 30.04% over the past year and 20.41% over the past 3 months, sitting 3.32% below its 52-week high with RSI at 73.92 (overbought). Q1FY27 results showed a 65.5% PAT surge on 28% revenue growth, drawing 6 positive items among the 8 news headlines tracked in early August 2026. The trailing PE of 88.34 is the highest among 6 tracked Pharma peers, against a mean analyst rating of 2.72 across 29 analysts (1-5 scale, lower = more constructive).
P/E
88.3
Forward P/E
57.1
ROE
—
Debt / Equity
0.04
Profit Margin
+26.1%
Div. Yield
+0.4%
5Y ROE > 15%
1/5
5Y FCF > 0
4/5
Quality
63/100
News
8 headlines · 6 positive · 0 negative
Divi's Laboratories posts 65% PAT surge in Q1FY27 on strong revenue growth - scanx.trade
scanx.trade
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
simplywall.st
Divi's Laboratories Ltd (BOM:532488) (Q1 FY27) Earnings Call Highlights: Record Profit Surge ... - finance.yahoo.com
finance.yahoo.com
Divi's Labs Q1 Results: Profit Jumps 65.5%, Revenue Up 28% - Key Numbers - NDTV Profit
NDTV Profit
Divi's Laboratories Limited Approves Senior Management Personnel Appointments, Effective on August 1, 2026 - marketscreener.com
marketscreener.com
Recent context
- ·Q1FY27 results (reported early August 2026) showed profit up 65.5% and revenue up 28%, prompting coverage across scanx.trade, NDTV Profit, simplywall.st, and Yahoo Finance between August 1 and August 6, 2026.
- ·The company approved senior management appointments effective August 1, 2026, per marketscreener.com.
- ·Mean analyst rating stands at 2.72 across 29 analysts (1-5 scale, lower = more constructive), alongside the recent earnings beat coverage.
Strengths
- +Q1FY27 PAT surged 65.5% YoY on 28% revenue growth, per results covered across NDTV Profit, scanx.trade, and Yahoo Finance between Aug 1-6, 2026.
- +5-year revenue growth of 27.8% and 5-year earnings growth of 65.7% outpace several sector peers.
- +Free cash flow was positive in 4 of the years tracked, and the price trades above both the 50-day (Rs 7,083.51) and 200-day (Rs 6,537.86) moving averages.
- +News flow over the tracked period is entirely non-negative (6 positive, 2 neutral, 0 negative of 8 headlines), including senior management appointments effective August 1, 2026.
Weaknesses
- −Trailing PE of 88.34 (forward 57.06) is the highest among the 6 Pharma peers tracked, ranking last (6th of 6) on that metric.
- −ROE has exceeded 15% in only 1 of the years tracked, with a consistency score of 50/100, and the debt trend is flagged 'rising' even though the absolute debt-to-equity ratio remains near zero.
- −RSI of 73.92 indicates overbought conditions, and the nearest identified support level (Rs 6,503.68) is 21.6% below the current price of Rs 8,300, a wide gap versus the single resistance level identified at Rs 8,585.
- −1-year price-change and some ROE data are missing for most of the 5 tracked Pharma peers, limiting how much of the sector ranking can be verified beyond PE and quality score.
Open questions
- ?Does the 65.7% 5-year earnings growth reflect a durable structural trend in the CDMO/API business, or a cyclical uplift tied to specific contracts or product cycles?
- ?How does the current trailing PE of 88.34 compare with DIVISLAB's own 5-year historical PE range, not just against sector peers?
- ?What is driving the 'rising' debt trend from a near-zero base, and what capex or expansion plans has management indicated behind it?
- ?With ROE above 15% in only 1 of the tracked years despite strong revenue and earnings growth, what factors (capital intensity, working capital cycle) explain the gap between growth and return-on-equity persistence?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| DIVISLAB | Divi's Laboratories Ltd.You're viewing | 88.3 | — | 57 |
| Industry avg | across 5 peers | 47.9 | +14.9% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 65.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 70.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 30.3 | +8.8% | 4 |
Technical state
Current price
₹8,300.00
SMA 50
₹7,083.51
SMA 200
₹6,537.86
RSI (14)
73.9 (overbought)
From 52w high
-3.3%
1Y return
+30.0%
3M return
+20.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumTrailing PE of 88.34 (forward PE 57.06) is the highest among the 6 Pharma peers tracked (Max Healthcare 70.51, Apollo Hospitals 65.03, Sun Pharma 38.56, Cipla 35.10, Dr. Reddy's 30.31), ranking 6th of 6 on the PE metric despite a quality score of 57 that ties for 1st in the sector.
- mediumROE has exceeded 15% in only 1 of the years tracked, with a consistency score of 50/100; the debt trend is flagged 'rising', though the absolute debt-to-equity ratio remains near zero (~0.0004x after adjusting the raw 0.042 percent-scale figure).
- lowRSI reads 73.92 (overbought); the 3-month price gain of 20.41% accounts for the bulk of the 30.04% 1-year gain, and the nearest identified support level (Rs 6,503.68) sits 21.6% below the current price of Rs 8,300, versus a single identified resistance level at Rs 8,585 (3.4% above current price).
- low1-year price-change figures are missing for all 5 tracked Pharma peers, and ROE is missing for Cipla and Sun Pharma, so sector ranking is only well-supported on the PE and quality-score dimensions.
Cross-section contradictions
- Quality score of 57 ties for 1st of 6 tracked Pharma peers, yet DIVISLAB carries the sector's highest trailing PE (88.34, rank 6th of 6) and ROE has exceeded 15% in only 1 of the tracked years (consistency score 50/100) - the quality ranking does not appear to be driven by valuation discipline or ROE persistence.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 11 Aug 2026 · rotates through NIFTY 500 every ~5 days